Premium
Is CD30 (Ki‐1) immunostaining in cutaneous eruptions useful as a marker of Th1 to Th2 cytokine switching and/or as a marker of advanced HIV‐1 disease?
Author(s) -
Kenneth J. Smith,
Barrett Tl,
Ronald C. Neafie,
Tomaszewski Mm,
Josef Yeager,
Ann Nelson,
Wagner Kf,
Skelton Hg
Publication year - 1998
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1046/j.1365-2133.1998.02212.x
Subject(s) - immunostaining , medicine , disease , human immunodeficiency virus (hiv) , pathology , immunology , cytokine , immunohistochemistry
CD30 is a member of the tumour necrosis factor/nerve growth factor receptor superfamily, which is expressed on CD4 + and CD8 + T‐cell clones which produce T helper (Th) 2‐type cytokines. It has been proposed that disease progression in HIV‐1 is associated with Th1 to Th2 cytokine switching. In 70 cutaneous biopsies from HIV‐1 positive patients in different stages of disease, we performed a battery of immunohistochemical stains. These included antibodies to CD3, UCHL‐1, OPD‐4, L‐26, KP‐1 and CD30 (Ki‐1). In addition, we used a similar battery of stains on cutaneous biopsies of HIV‐1 negative patients with inflammatory dermatoses which are established as Th1 or Th2 dominant, e.g. polar leprosy. CD30 + cells were rarely present in early stages of HIV‐1 disease, but commonly present in later stages of disease. However, there were cases of late HIV‐1 disease which did not contain CD30 + cells. Increased numbers of CD30 + cells were more commonly seen in later stages of HIV‐1 disease. However, the expression of CD30 appeared to be better in predicting other established Th2 cutaneous infiltrates in HIV‐1 negative patients than in predicting a Th2 cutaneous cytokine pattern in advanced HIV‐1 disease.